褪黑素辅助治疗葡萄膜黑色素瘤(AMUM):一项随机开放标签III期研究方案
本研究为在St. Erik眼科医院开展的开放标签、前瞻性、5年随机对照试验,计划纳入100例近期诊断的非转移性葡萄膜黑色素瘤患者,随机分为辅助褪黑素20 mg(5 mg片剂4片)晚10点服用5年组或标准随访对照组。主要结局为随机化后5年发生转移的相对风险,次要结局包括总生存期、发生其他癌症的风险、转移后总生存期及不良事件和严重不良事件发生率的组间差异。
要点
- 褪黑素20 mg(5 mg片剂4片)晚10点服用5年,对照为标准随访。
- 主要结局为随机化后5年发生转移的相对风险。
- 次要结局包括总生存期、其他癌症风险、转移后生存及不良事件差异。
核心结论
- 旨在探究非转移性葡萄膜黑色素瘤诊断后辅助褪黑素治疗5年能否降低转移发生率。
研究设计与样本
- 开放标签、前瞻性、5年随机对照试验,在St. Erik眼科医院开展,计划纳入100例近期诊断的非转移性葡萄膜黑色素瘤患者。
主要发现
- 原文为研究方案,尚未报告研究结果。
关键数值与推荐
- 干预组:辅助褪黑素20 mg(5 mg片剂4片)晚10点服用5年;对照组:标准随访。
- 主要结局:随机化后5年发生转移的相对风险;次要结局:总生存期、发生其他癌症的风险、转移后总生存期、不良事件和严重不良事件发生率的组间差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uveal melanoma is the most common primary intraocular tumor in adults. In Sweden, at least 100 patients are diagnosed with the disease each year. Almost half of the patients develop metastases, with a median survival time of 1 year once metastases are detected. The primary ocular tumor is typically treated with either enucleation or brachytherapy, and no adjuvant treatment is added. Melatonin is an indolamine hormone that has improved survival in previous trials with patients diagnosed with various cancers, including advanced cutaneous melanoma. Side effects have been mild. We aim to investigate if adjuvant treatment with melatonin for 5 years following diagnosis of non-metastasized uveal melanoma can decrease the occurrence of metastases. METHODS: An open-label, prospective, 5-year randomized clinical trial (RCT) will be conducted at St. Erik Eye Hospital. One hundred patients recently diagnosed with non-metastatic uveal melanoma will be randomized to either treatment with adjuvant melatonin 20 mg (4 tablets of 5 mg) at 10 pm for 5 years, or to standard follow-up (control group). The primary outcome measurement is the relative risk for having developed metastases 5 years after randomization. The secondary outcomes are overall survival, risk of developing other cancers, overall survival after detection of metastases, and differences in the occurrence of adverse events (AE) and serious adverse events (SAE) between the groups. DISCUSSION: Melatonin has been found to positively impact our immune system, inhibit angiogenesis, stimulate apoptosis in malignant cells, and act as a potent antioxidant. Previous clinical trials have used similar doses of melatonin with positive results, particularly in advanced stages of cancer. Previous animal and human studies have found the toxicity of the hormone to be low. Considering the potential benefits and limited risks of melatonin, as well as its global availability, it may be a suitable candidate for an adjuvant treatment in patients with uveal melanoma. TRIAL REGISTRATION: Our trial protocol has been approved and registered by the Swedish Medical Products Agency on June 22, 2022 (EudraCT 2022-500,307-49-00). Our trial registration number is NCT05502900, and the date of registration is August 16, 2022.
引用
- Kal Omar R, Hagström A, Stålhammar G, et al. Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study. Trials. 2023. PMID: 36966349. doi:10.1186/s13063-023-07245-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。